Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F....
-
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition,...
-
Presentation to highlight updated interim data from global trial in patients with metastatic cutaneous squamous cell carcinomaOver 50% of enrollment target achieved; full enrollment expected around...
-
NEW YORK, May 22, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will...
-
Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition,...
-
- U.S. patent protection through at least May 2038- Registration-enabling study of cosibelimab in cutaneous squamous cell carcinoma over one-third enrolled NEW YORK, April 21, 2020 (GLOBE NEWSWIRE)...
-
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
-
FDA feedback supports plan to submit Biologics License Application (BLA) based on data from ongoing Phase 1 trialOne-third enrollment complete in cohort of patients with metastatic cutaneous squamous...
-
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of...
-
NEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is...